Vycor Medical Reports Mixed Financial Results, Highlights Clinical Evidence for Brain Access System

Vycor Medical, Inc. (OTCQB: VYCO), a Boca Raton-based medical device company, released its financial results for the three and six months ended June 30, 2026, revealing a mixed performance across its two business units. The company operates Vycor Medical, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, and NovaVision, a developing therapy program for visual disorders after stroke or brain injury.

For the second quarter of 2026, total revenue decreased 16% to $418,264 from $496,353 in the same period last year. The Vycor Medical division saw a 17% decline in revenue to $401,224, with the decrease attributed entirely to international markets. In contrast, NovaVision generated $17,040 in revenue, a 17% increase over the prior year. For the first half of 2026, total revenue fell 6% to $876,804, with Vycor Medical revenue down 7% to $841,665, split between US and international markets, while NovaVision rose 8% to $35,139.

Gross profit margins remained robust at 82% for the quarter and first half, slightly down from 83% in the prior year periods. Operating profit for the quarter was $6,851, a significant drop from $51,146 in 2025, but for the six months, operating profit increased to $52,659 from $38,340. On a non-GAAP basis, which excludes non-cash depreciation and stock-based compensation, operating profit was $22,952 for the quarter and $82,740 for the six months, compared to $85,712 and $106,100 in the 2025 periods, respectively.

Despite the revenue dips, Vycor Medical highlighted significant clinical advancements. During 2026, three new peer-reviewed studies were published on the VBAS, bringing the total to 53 peer-reviewed papers and 14 other clinical papers. One study focused on a complex pediatric tumor case, emphasizing that integrating neuro-navigation systems with VBAS was “a paramount strategy for the surgical resection” of such lesions. Another retrospective study of 23 patients compared VBAS to traditional blade retractors and found significantly fewer new neurological deficits at follow-up for the tubular retractor group, implying safer tumor resection with VBAS. The most recent paper reported on a single-center study of 29 adults undergoing minimally invasive suboccipital tubular resection of posterior fossa metastases, concluding that this approach enables effective decompression with low cerebrospinal fluid diversion rates.

These clinical validations are crucial for the adoption of VBAS, which is FDA-cleared and used in over 350 US hospitals and internationally. The system is protected by 49 issued and 8 pending patents. NovaVision, though still in development, offers the only FDA-cleared Visual Restoration Therapy for vision rehabilitation after neurological damage, along with the NeuroEyeCoach program, which has shown improvement in over 80% of patients in a 296-patient study.

Management noted that international sales can be lumpy, with large orders sometimes falling in different quarters, which may explain the revenue volatility. The company continues to focus on expanding its clinical evidence base to support surgeon adoption and improve patient outcomes. As these studies accumulate, they could influence surgical practices and potentially drive future demand for VBAS, impacting the neurosurgical device market.